期刊文献+

依维莫司分散片的制备及质量考察 被引量:1

Preparation and Quality Control of Everolimus Dispersible Tablets
下载PDF
导出
摘要 目的制备依维莫司分散片并建立其质量控制方法。方法用固体分散技术和流化床技术制备依维莫司分散片,采用高效液相色谱法测定其含量、有关物质和溶出度,建立依维莫司分散片质量控制方法。结果依维莫司分散片在1min内全部崩解,分散性均匀,45min溶出达85%以上。在高效液相色谱法含量测定中,依维莫司在100~1200μg·m L^(-1)范围线性良好,平均回收率为99.26%,RSD为0.52%;在溶出测定中,依维莫司在1.0~12.0μg·m L^(-1)范围线性良好,平均回收率为100.32%,RSD为0.67%。结论本品制备工艺简单,质量控制方法准确,质量符合药典要求。 OBJECTIVE To prepare everolimus dispersible tablets and establish a method for its quality control. Method:The everolimus dispersible tablets were prepared by the technique of solid dispersions and the fluidized-bed. The content,related substance and dissolution of the everolimus dispersible tablets were determined by HPLC,and its quality control method was established. RESULTS The everolimus dispersible tablets could completely disintegrate within 1 minute,and the dispersible uniform was excellent,and its dissolution was more than 85%with 45 minutes. A good linear relationship was obtained in the range of 100 ~ 1200μg·m L^(-1)with the average recovery of 99. 26%( RSD = 0. 52%). The dissolution sample showed a good linear relationship at a range of 1. 0 ~12. 0μg·m L^(-1)with the average recovery of 100. 32%( RSD = 0. 67%). CONCLUSIONS The preparing technique of the everolimus dispersible tablets is simple. The quality control method is accurate,and its quality meets the requirements of Pharmacopoeia.
作者 陈有钟
出处 《海峡药学》 2016年第3期26-29,共4页 Strait Pharmaceutical Journal
基金 福建省科技计划重点项目<新型mTOR靶向抗癌药物依维莫司分散片的研究>(编号2013Y0014)的研究论文
关键词 依维莫司 分散片 溶出度 质量控制 Everolimus Dispersible tablet Dissolution Quality control
  • 相关文献

参考文献5

二级参考文献25

  • 1FAIVRE S, KROEMER G, RAYMOND E. Current developmentof mTOR inhibitors as anticancer agents [ J ]. Nat Rev Drug Dis-cov, 2006,5(8) : 671 -688.
  • 2SANCHEZ-FRUCTUOSO AL Everolimus: an update on the mech-anism of action,pharmacokinetics and recent clinical trials [ J ].Expert Opin Drug Met, 2008,4(6) : 807 - 819.
  • 3JOHNSTON SR. Clinical efforts to combine endocrine agents withtargeted therapies against epidermal growth factor receptor/humanepidermal growth factor receptor 2 and mammalian target of rapa-mycin in breast cancer [ J ] . Clin Cancer Res,2006, 12(3):1061s- 1068s.
  • 4BURSTEIN HJ. Novel agents and future directions for refractorybreast cancer[ J]. Semin Oncol f 2011, 38(Suppl): sl7 - s24.
  • 5BOULAY A,RUDLOFF J, YE J, et al. Dual inhibition of mTORand estrogen receptor signaling in vitro induces cell death in mod-els of breast cancer [ J ]. Clin Cancer Res, 2005,11 ( 14 ):5319 -5328.
  • 6O’DONNELL A, FAIVRE S, BURRIS HA, et al. Phase I phar-macokinetic and pharmacodynamic study of the oral mammaliantarget of rapamycin inhibitor everolimus in patients with advancedsolid tumors[J]. J Clin Oncol, 2008, 26(10) : 1588 - 1595.
  • 7JACOBSEN W, SERKOVA N, HAUSEN B, et al. Comparisonof the in vitro metabolism of the macrolide immunosuppressantssirolimus and RAD [ J] . Transplant Proc,2001,33 ( 1 - 2 ):514 -515.
  • 8KOVARIK JM, SABIA HD,FIGUEIREDO J, et al. Influence ofhepatic impairment on everolimus pharmacokinetics : implicationsfor dose adjustment [ J ]. Clin Pharmacol Ther,2001,70 ( 5 ):425 -430.
  • 9TABEKNKHO J, ROJO F, CALVO E, et al. Dose-and sched-ule-dependenl inhibition of ihe mammalian target of tapamycinpathway with everolimus : a phase 1 tumor pharmacodynamic studyin patients with advanced solid tumors [ J ]. J Clin Oncol, 2008 ,26(10) : 1603 - 1610.
  • 10STEIN A, WANG W , CARTER A, et al. Dynamic tumor model-ing of ihe dose-response relationship for everolimus in metastaticrenal cell (,ar(、immia using data from the phase 3 RKCORD-1 trial[J]. BMC Cancer, 2012, 12(1): 311 -320.

共引文献11

同被引文献34

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部